Vise Technologies Inc. Purchases 50,231 Shares of Pfizer Inc. $PFE

02 Nov 2026, 14:28 by Tristan Rich · The Markets Daily

Vise Technologies Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 16.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 364,384 shares of the biopharmaceutical company’s stock after acquiring an additional 50,231 shares during the quarter. Vise Technologies Inc.’s holdings in Pfizer were worth $10,392,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Bank of America Corp DE purchased a new position in Pfizer during the 2nd quarter worth $1,049,602,000. BlackRock Inc. increased its stake in shares of Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after buying an additional 31,412,883 shares during the period. Nykredit A S purchased a new position in shares of Pfizer during the second quarter valued at $205,774,000. Assenagon Asset Management S.A. raised its holdings in shares of Pfizer by 96.0% in the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after acquiring an additional 5,829,204 shares in the last quarter. Finally, State Street Corp lifted its stake in Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after acquiring an additional 5,501,032 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 0.1%

NYSE:PFE opened at $30.48 on Monday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $30.67. The company has a market cap of $173.73 billion, a PE ratio of 40.11, a P/E/G ratio of 2.07 and a beta of 0.31. The company’s 50 day moving average is $28.55 and its two-hundred day moving average is $26.79.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Cantor Fitzgerald increased their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Finally, BMO Capital Markets lowered their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.65.

Read Our Latest Analysis on Pfizer

About Pfizer

(Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.